A Phase III Trial of Pegcantratinib in Patients with Psoriasis
Latest Information Update: 06 Aug 2019
At a glance
- Drugs Pegcantratinib (Primary)
- Indications Psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Sienna Biopharmaceuticals
Most Recent Events
- 05 Aug 2019 According to a Sienna Biopharmaceuticals media release, the company will continue to explore capital raising to enable the initiation of the planned Phase 3 pivotal clinical trials for SNA-120 (pegcantratinib; CT profile 232992 and 305470), in addition to exploring a wide range of financial and strategic alternatives.The company does not intend to initiate these planned phase 3 trials of SNA-120 until the company secures sufficient additional capital.
- 10 Jun 2019 According to a Sienna Biopharmaceuticals media release, first patient enrollment is anticipated in the second half of 2019.
- 20 Mar 2019 New trial record